| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
SVP, Finance &Accounting
1 company
Doyle Thomas James is a SVP, Finance &Accounting at KURA. Recent filings cover 0 purchases and 12 sales. Those positions are worth an estimated $1.5M at current prices.
Our model assigns Doyle Thomas James a below-average insider score of 48/100, based on 5 past trades. Over a 12-month horizon, 33.3% of those trades were profitable, with an average 12-month return of +7.6%.
Doyle Thomas James's largest disclosed position is in KURA as SVP, Finance &Accounting, worth about $1.5M. The recent filings there lean toward selling, a net 22,502 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 28, 2026 | KURA Kura Oncology, Inc. | SVP, Finance &Accounting | Sell | 4,607 | $10.50 | $48,360.60 | -3.1% | - | - | |
| Nov 14, 2025 | KURA Kura Oncology, Inc. | SVP, Finance &Accounting | Sell | 4,539 | $11.18 | $50,731.95 | -3.4% | -28.4% | - | |
| Sep 29, 2025 | KURA Kura Oncology, Inc. | SVP, Finance &Accounting | Sell | 4,541 | $8.94 | $40,606.53 | -4.0% | +16.5% | - | |
| Jan 28, 2025 | KURA Kura Oncology, Inc. | SVP, Finance &Accounting | Sell | 4,949 | $7.87 | $38,958.03 | -5.3% | -16.2% | +3.5% | |
| Jan 29, 2024 | KURA Kura Oncology, Inc. | SVP, Finance &Accounting | Sell | 2,318 | $17.80 | $41,261.56 | -4.6% | +7.8% | -58.2% | |
| Jan 27, 2023 | KURA Kura Oncology, Inc. | SVP, Finance &Accounting | Sell | 1,548 | $13.89 | $21,501.76 | -8.4% | -29.5% | +31.8% |